Department of Surgery, Michigan Medicine, Ann Arbor, Michigan, USA.
J Surg Oncol. 2021 Mar;123(3):775-781. doi: 10.1002/jso.26319.
Merkel cell carcinoma (MCC) is an aggressive form of skin cancer which, while chemosensitive, has high rates of relapse and chemoresistance, limiting the impact of chemotherapy. An immunogenic tumor, the management of advanced MCC has changed dramatically with the introduction of checkpoint inhibitors. This review will focus on the impact of immunotherapy in unresectable and metastatic MCC, ongoing research in the adjuvant and neoadjuvant settings, and future directions of immune-based strategies for this challenging cancer.
默克尔细胞癌（Merkel cell carcinoma，MCC）是一种侵袭性皮肤癌，对化疗敏感，但复发率和化疗耐药率高，限制了化疗的作用。作为一种免疫原性肿瘤，随着检查点抑制剂的引入，晚期 MCC 的治疗发生了巨大变化。本文将重点讨论免疫疗法在不可切除和转移性 MCC 中的作用、辅助和新辅助治疗中的研究进展，以及针对这种具有挑战性的癌症的免疫策略的未来方向。
Zotero 插件